Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BeiGene, a Chinese life sciences biotechnology company, has signed in-licensing and co-development deals with Janssen Pharmaceutica NV and its affiliates for two clinical-stage oncology compounds.
Subscribe to our email newsletter
According to the deal, BeiGene will in-license intetumumab (CNTO-95) for clinical development and commercialization within Australia, China, Hong Kong, New Zealand, Korea, Singapore and Taiwan.
Intetumumab is a fully humanized monoclonal antibody against av integrins that binds to human integrins, helping disruption of tumor cell growth, development and metastases.
BeiGene will also in-license MTKi-327 and retain global rights for development and commercialization for human pharmaceutical uses.
MTKi-327 is a macrocyclic multi-targeted kinase inhibitor of many critical cancer signaling pathways.